A new category of antibiotics for the treatment of bloodstream infections

Scientists at the Swedish University of Oppsala have discovered a new group of antibiotics, with a strong activity against multiple medicine -resistant bacteria, which can treat bloodstream infections in mice, according to a study published by the reality of the National Academy of Sciences. This new category is aimed at a protein known as LPXH, which is used by a bacterium that negative grams create an external protection layer, performed by environmental fluctuations, and prevent medicine from reaching. Internal toxins participate in the biological composition of a boat called ‘sebaceous’, which is one of the important components of the outer membrane of bacteria negative grams, and also plays a decisive role in the structural safety of the bacterial rare coverage, and also works as an internal sole, leading to immune response. All bacteria do not produce this layer, but the organisms produced by the World Health Organization as the most important to develop new treatments for them, including Coli -Coli, and Pulmonary Albumsla that have already developed resistance to available antibiotics, which pose a major threat to human health around the world. Eye -coli and pulmonary al -kelcorla can produce enzymes known as ‘beta lactamaz’, which can dissolve the beta lactam -antibiotics, such as penicillin and cephalosporin, which makes it ineffective. Antibiotics are also some of the coli and the pulmonary cellastila tribes produce the tisted spectrum of beta lactamase -enzymes, which are the watery decomposition of a wide variety of beta lactam antibiotics, including the third generation of sea palosporins and monobacheam. Although the LPXH itself does not resist antibiotics, the mutations in the genes involving the enzymes involved in the biological creation of bacterial membranes can indirectly affect. According to the researchers, this protein can change the permeability of the external membrane of bacteria, which can affect the entry of antibiotics in the bacterial cell. It is known that antibiotics are the basis of modern medicine, as people have saved people’s lives all over the world over the past century. Nowadays, antibiotic doctors are essential compounds that are largely relied on to treat or prevent bacterial infections, including, for example, the risk of infection during cancer treatment, during gas operations and organ transplants, as mothers as well as premature children. Antibiotic resistance, but the global increase in antibiotic resistance threatens its effectiveness, so it has become necessary to develop new treatments that have no resistance. According to the study, this compound category is completely new, and the LPXH protein has not yet been used as a target of antibiotics, and so there is no existing resistance to this category of vehicles, as opposed to many antibiotics currently in the clinical development phase. Although the current results are very promising, an extra job will be needed before the compounds of this category are ready for clinical trials.